Thursday 7 April 2022

March 2022 portfolio update

Portfolio activity - March 2022:

Buy

Add

Sell

 Legal & General

None 

None 

 Life Sciences REIT

 

 

Portfolio performance - March 2022

The portfolio: +1.6% 
Benchmark: +1.4%

Rolling 12 month portfolio dividend yield: 3.2%
Benchmark dividend yield: 3.06%

Portfolio valuation change since start - March 2022
Portfolio: +37%
Benchmark: +15.7%

Portfolio

company

% of portfolio

computacenter

6.7%

unilever

6.0%

impact healthcare

5.8%

glaxosmithkline

4.2%

anglo pacific

4.1%

telecom plus

3.9%

tritax big box

3.6%

national grid

3.5%

hend. far east income

3.4%

relx

3.3%

somero enterprises

3.1%

diageo

2.8%

compass

2.5%

jpm asia income & growth

2.4%

abcam

2.4%

british american tobacco

2.4%

tate & lyle

2.3%

reckitt benckiser

2.3%

legal and general

2.3%

euromoney

2.2%

schroders

2.1%

qinetiq

2.0%

duke royalty

2.0%

nichols

2.0%

ag barr

1.8%

smith & nephew

1.8%

hargreaves lansdown

1.5%

rws holdings

1.3%

eleco

1.3%

jersey electricity

1.2%

homeserve

1.2%

888 holdings

1.1%

life sciences reit

1.1%

blackbird

0.8%

craneware

0.8%

lancashire holdings

0.7%

ab dynamics

0.5%